CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.42
+3.65%Margins
Gross margin
63.6%
EBITDA margin
-291.5%
EBIT margin
-307.4%
Net margin
-257.1%
FCF margin
-478.9%
-215.3%
Return on equity
-68.5%
Return on assets
-158.9%
Return on invested capital
0.22x
Asset turnover
-$243.9M
Cash from operations
$0.68
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026